(112 days)
The Swift™ Air channels airflow noninvasively to a patient from a positive airway pressure (PAP) device such as a continuous positive airway pressure (CPAP) or bilevel device.
The Swift Air is:
- to be used by patients (> 66 lb/30 kg) for whom positive airway pressure has been prescribed
- intended for single-patient re-use in the home environment and multipatient re-use in the hospital/institutional environment.
The Swift™ Air provides an interface such that air flow from a positive pressure source is directed to the patient's nasal nares. The mask is held in place with adjustable headgear that straps the mask to the face.
Swift™ Air is a prescription device supplied non-sterile.
This document describes the premarket notification for the ResMed Swift™ Air nasal mask. The acceptance criteria and supporting studies are based on demonstrating substantial equivalence to predicate devices, rather than establishing de novo performance metrics.
1. Table of Acceptance Criteria and Reported Device Performance
| Acceptance Criteria Category | Predicate Device(s) | Acceptance Criteria | Reported Device Performance (Swift™ Air) |
|---|---|---|---|
| Intended Use | Mirage FX (K102746) | Identical intended use as the predicate device, for use with Positive Air Pressure therapy equipment and the same patient population. | Identical intended uses: Channels airflow noninvasively to a patient from a PAP device (CPAP or bilevel), for patients > 66 lb/30 kg, single-patient re-use in home, multi-patient re-use in hospital/institutional environment. |
| Biocompatibility | Swift™ FX (K090244) | All materials used in the construction must be deemed as safe as those of the predicate devices, in accordance with FDA Guidance #G95-1 and ISO 10993-1. Specific tests for heated humidified gas pathway (ISO 10993-3, -5, -6, -10) and skin contact (ISO 10993-5, -10). | All materials used in the construction of the new mask are deemed as safe as those of the predicate devices. Appropriate biological tests (ISO 10993-3 Genotoxicity, ISO 10993-5 Cytotoxicity, ISO 10993-6 Implantation, ISO 10993-10 Sensitization for heated gas pathway; ISO 10993-5 Cytotoxicity, ISO 10993-10 Sensitization and Irritation for skin contact) were conducted and passed. |
| CO2 Performance (Venting) | Ultra Mirage II (K050359) | Adequate venting to flush out expired CO2, satisfying predefined pass/fail criteria and being substantially equivalent to the predicate device. | CO2 performance of the new device (both vent types) was tested, including physical and functional dead-space measurements. The device satisfied all predefined pass/fail criteria and was shown to be substantially equivalent to the predicate Ultra Mirage II. |
| Pressure-Flow Characteristics & Flow Impedance | Swift™ FX (K090244) | Identical pressure-flow characteristics and flow impedance to the predicate device, operating on the same ResMed flow generator settings. | Pressure-flow and through impedance bench test results of the new mask were substantially equivalent to the predicate Swift FX. |
| Mechanical Integrity & Performance | (General Safety) | Withstand simulated normal use and reasonable abuse scenarios, and the effects of storage temperature, humidity, and transportation shock & vibration. | Mechanical integrity and performance were tested to simulated normal use and reasonable abuse scenarios. The device was tested to demonstrate it can withstand storage temperature, humidity, and transportation shock & vibration. Device development complies with ISO 14971:2007 (risk management). |
| Cleaning and Reuse | (General Safety) | Device can be safely reused (single-patient home, multi-patient hospital) following validated disinfection protocols, and function as intended after specified cleaning/disinfection cycles. | Validation of cleaning and reuse was completed. After 20 cycles of cleaning/disinfection in accordance with described methods, the device was shown to function as intended. The device satisfied pass/fail criteria and was shown to be substantially equivalent to the predicate devices. |
2. Sample Size Used for the Test Set and Data Provenance
The review document does not specify a "test set" in the context of clinical data for performance evaluation of the Swift™ Air mask. The evaluation relied heavily on bench testing and comparison to predicate devices to demonstrate substantial equivalence.
- Clinical Data: "Use of vented nasal masks with CPAP or Bilevel therapy is proven technology and is well accepted by the medical community. Bench testing is sufficient to demonstrate substantial equivalence to the predicate devices." This indicates no new clinical studies with a specific patient "test set" were conducted for the Swift™ Air for this submission.
- Bench Testing: The sample sizes for the various bench tests (CO2 performance, pressure-flow, mechanical integrity, cleaning/reuse) are not explicitly stated in the provided text. The data provenance is presumed to be internal laboratory testing conducted by ResMed.
3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications
Not applicable. As noted above, the evaluation was based on bench testing and comparison to predicate devices, not on expert-adjudicated clinical patient data or specific "ground truth" established by experts for a test set.
4. Adjudication Method for the Test Set
Not applicable. There was no clinical "test set" requiring expert adjudication.
5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study
No. An MRMC study was not performed. This device is a medical accessory, and its effectiveness is determined by its physical and functional characteristics in delivering CPAP/Bilevel therapy, rather than diagnostic interpretation requiring human readers.
6. Standalone Performance Study (Algorithm only without Human-in-the-Loop Performance)
Yes, implicitly. The performance data presented (CO2, pressure-flow, mechanical integrity, cleaning/reuse) represents the "standalone" performance of the device itself, under bench test conditions. This is the equivalent of "algorithm only" in the context of a physical medical device.
7. Type of Ground Truth Used
The "ground truth" for the Swift™ Air device in this submission was established by:
- Predicate Device Performance: The primary "ground truth" was the established performance and safety profiles of the predicate devices (Mirage FX, Swift™ FX, Ultra Mirage II) that have already been cleared by the FDA.
- Industry and Regulatory Standards: Adherence to standards such as FDA Guidance #G95-1, ISO 10993-1 (Biocompatibility), ISO 14971:2007 (Risk Management), and ISO 5356-1:2004 (Conical Connectors) served as additional "ground truth" for safety and performance requirements.
- Predefined Pass/Fail Criteria: For the bench tests (e.g., CO2 performance, mechanical integrity), "predefined pass/fail criteria" were used as the immediate ground truth, though these criteria would have been derived from relevant standards and predicate performance.
8. Sample Size for the Training Set
Not applicable. There is no mention of a "training set" in the context of this device. This is a physical medical device, not an AI/ML algorithm that requires a training set.
9. How Ground Truth for the Training Set Was Established
Not applicable. As there was no training set, there was no ground truth for a training set to be established.
{0}------------------------------------------------
K13.2013
RESMED
Swift Air Traditional 510(k)
| 510(k) SUMMARY[As required by 21 CFR 807.92(c)] | |
|---|---|
| Date Prepared | June 28th, 2013 |
| Submitter Name | Mr. Kim Kuan LEE |
| Official Contact | Mr. Jim CassiVice President - Quality Assurance Americas9001 Spectrum Center BlvdSan Diego CA 92123 USATel: (858) 836 6081 |
| Device Trade Name | Swift™ Air |
| Device Common Name/Classification Name | Vented Nasal Mask;Accessory to Noncontinuous Ventilator (IPPB) |
| Classification | 21 CFR 868.5905, 73 BZD (Class II) |
| Predicate Devices | Mirage FX (K102746)Swift™ FX (K090244)Ultra Mirage II (K050359) |
| Description | The Swift™ Air provides an interface such that air flow from apositive pressure source is directed to the patient's nasal nares.The mask is held in place with adjustable headgear that straps themask to the face.OCT 2 1 2013 |
| Swift™ Air is as safe as the predicate devices when used underthe conditions and purposes intended as indicated in the labellingprovided with the product. | |
| Swift™ Air is a prescription device supplied non-sterile. | |
| Intended Use | The Swift™ Air channels airflow noninvasively to a patient from apositive airway pressure (PAP) device such as a continuouspositive airway pressure (CPAP) or bilevel device.The Swift™ Air is:to be used by patients (> 66 lb/30 kg) for whom positiveairway pressure has been prescribedintended for single-patient re-use in the home environmentand multipatient re-use in the hospital/institutionalenvironment. |
| Intended Use comparison | Comparison with predicate Mirage FX (K102746)The new device and the predicate Mirage FX mask have identicalintended uses. Both are intended to be used with Positive AirPressure therapy equipment and for the same identical patientpopulation. |
| TechnologicalCharacteristicscomparison | Comparison with predicate Swift™ FX (K090244)The new device and the predicate mask, provide a seal via asilicone interface. The design of both devices incorporate a pillowsthat seals under the patient's nasal nares. Both masks are offered |
28" June 2013
510(k) Page# 17
{1}------------------------------------------------
in multiple sizes to ensure adequate fit over the extended patient population.
The main differences with the new device are:
(a) It offers two vent options, a traditional multi-hole vent and a new diffused type vent to provide a continuous air leak to flush out and minimize the amount of CO2 re-breathed by the patient. Like the predicate mask, the incorporation of these exhaust vents does not interfere with the intended performance of the new device. (b) The number of components and overall weight is reduced. (c) The headgear includes a rigidizer component.
Both masks connect to a conventional air delivery hose between the mask and the positive airway-pressure source via standard conical connectors (ref: ISO 5356-1:2004).
Both masks are constructed of molded plastic and silicone components and fabric / nylon headgear that have been subject to biocompatibility safety evaluation in accordance with FDA Guidance #G95-1 and ISO 10993-1. All materials used in the construction of the new mask are deemed as safe as those of the predicate devices.
Materials used in the construction of components that contact the heated humidified gas pathway are classified as permanent "external communicating devices" (with tissue/bone/dentin). The appropriate biological tests conducted and passed for these components, in accordance with FDA guidance #G95-1 were:
- ISO 10993-3 Genotoxicity, .
- ISO 10993-5 Cytotoxicity, .
- ISO 10993-6 Implantation and .
- ISO 10993-10 Sensitization. .
The appropriate biological tests conducted and passed for components considered to be in permanent skin contact, in accordance with FDA guidance #G95-1, were:
- ISO 10993-5 Cytotoxicity .
- ISO 10993-10 Sensitization and Irritation
In addition, development of the Swift™ Air device complies with ISO 14971:2007, Medical devices - Application of risk management to medical devices.
Both the new mask and the predicate device are designed to operate on the same Pillows, Mirage or Swift ResMed flow generator settings. The pressure-flow characteristics and flow impedance of both devices are identical.
Both the new mask and the predicate device can be reused in the home and hospital / institution environment.
Performance Data Comparison with predicate Ultra Mirage II (K050359) The CO2 performance of the new device (both vent types) and the predicate Ultra Mirage II device are substantially equivalent.
{2}------------------------------------------------
Non-clinical testing data The CO2 performance of the new device was tested to ensure the mask design provides adequate venting to flush out the expired CO2. The testing included physical and functional dead-space measurements. The device satisfied all predefined pass/fail criteria and was shown to be substantially equivalent to the predicate Uitra Mirage II (K050359) device as described previously. Pressure-flow and through impedance bench test results of the new mask were also substantially equivalent to the predicate Swift FX (K090244) device. Mechanical integrity and performance of the new device was tested to simulated normal use and reasonable abuse scenarios. The device was also tested to demonstrate that it can withstand the effects of storage temperature, humidity and transportation shock & vibration. Validation of cleaning and reuse was completed to establish that the device can be safely reused by a single patient, or multipatient reuse in the hospital/institutional environment following validated disinfection protocols. After 20 cycles of cleaning/disinfection in accordance with the methods described in the cleaning / disinfection guide, the device has been shown to function as intended. The device satisfied the passifail criteria and was shown to be substantial equivalent to the predicate devices. Use of vented nasal masks with CPAP or Bilevel therapy is Clinical Data proven technology and is well accepted by the medical community. Bench testing is sufficient to demonstrate substantial equivalence to the predicate devices. The new Swift™ Air is as safe and as effective as the predicate Substantial Equivalence Conclusion devices: it has the same intended use: l it has identical technological characteristics to the predicate devices: ﺖ the new device did not raise any new questions of safety or effectiveness: it is at least as safe and as effective as the predicate devices.
{3}------------------------------------------------
Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of two main elements: the department's name arranged in a circular fashion and an emblem. The emblem features a stylized caduceus-like symbol, with three wavy lines representing the staff and a single snake winding around it. The text reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA".
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
October 21, 2013
ResMed Corporation Jim Cassi Vice President. Ouality Assurance Americas 9001 Spectrum Center Blvd. SAN DIEGO, CA 92123
Re: K132013
Trade/Device Name: Swift™ Air Regulation Number: 21 CFR 868.5905 Regulation Name: Vented Nasal Mask; Accessory to Non-continuous Ventilator Regulatory Class: Class II Product Code: BZD Dated: July 22, 2013 Received: July 23, 2013
Dear Mr. Cassi:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
{4}------------------------------------------------
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its tollfree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note
the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Image /page/4/Picture/6 description: The image shows a signature and some text. The text includes the phrase "Sincerely yours," followed by the name "Tejashri Purohit-Sheth, M.D." The text also includes the title "Clinical Deputy Director" and the acronym "DAGRID." Finally, the letters "FOR" are at the bottom right.
Kwame Ulmer, M.S. Acting Division Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{5}------------------------------------------------
RESMED
Swift Air Traditional 510(k)
Indication for Use
| 510(k) Number (if known): | |
|---|---|
| Device Name: | Swift TM Air |
| Indication for Use |
The Swift™ Air channels airflow noninvasively to a patient from a positive airway pressure (PAP) device such as a continuous positive airway pressure (CPAP) or bilevel device.
The Swift Air is:
- to be used by patients (> 66 lb/30 kg) for whom positive airway pressure has been prescribed .
- intended for single-patient re-use in the home environment and multipatient re-use in the . hospital/institutional environment.
| Prescription Use(Part 21 CFR 801 Subpart D) | X | AND/OR | Over-The-Counter Use(Part 21 CFR 807 Subpart C) |
|---|---|---|---|
| ------------------------------------------------- | ---------- | -------- | ----------------------------------------------------- |
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
| K132013 | Concurrence of CDRH; Office of Device Evaluation (ODE) |
|---|---|
| Digitally signed by Anya C. Harry-S DN: c=US, o=U.S. Government, ou=HHS, ou=FDA, ou=People, cn=Anya C. Harry -S, 0.9.2342.19200300.100.1.1=0011315590 Date: 2013.10.18 16:25:29 -04'00' | |
| Anya C. Harry -S | Page 1 of 1 |
| 28 th June 2013 | 510(k) Page# 15 |
§ 868.5905 Noncontinuous ventilator (IPPB).
(a)
Identification. A noncontinuous ventilator (intermittent positive pressure breathing-IPPB) is a device intended to deliver intermittently an aerosol to a patient's lungs or to assist a patient's breathing.(b)
Classification. Class II (performance standards).